Indications
For adults: as part of combined therapy for the treatment and prevention of diseases accompanied by connective tissue hyperplasia:
in gynecology: treatment and prevention of adhesions in the pelvis in chronic inflammatory diseases of the internal genital organs, including tuboperitoneal infertility, uterine synechiae, chronic endometritis
in urology: treatment of chronic prostatitis, interstitial cystitis
in surgery: treatment and prevention of adhesions after surgical interventions on abdominal organs and long-term non-healing wounds
in dermatovenerology and cosmetology: treatment of localized scleroderma, non-infectious onychodystrophy, keloid, hypertrophic scars after pyoderma, injuries, burns, surgeries, Grade II-IV acne vulgaris with cicatricial deformities (post-acne)
in pulmonology and phthisiology: treatment of pneumosclerosis, fibrosing alveolitis, tuberculosis (fibrocavernous TB, infiltrative TB, tuberculoma)
in rheumatology: treatment of joint contracture, including Dupuytren's contracture and flexion tendogenic contracture of the hand, arthrosis, ankylosing spondylitis, hematomas
for enhancing bioavailability: when administered concomitantly with antibacterial agents in urology, gynecology, surgery, dermatovenerology, pulmonology, to enhance the effect of local anesthetics.

Preparation of the solution:
1. For subcutaneous or intramuscular injection: dissolve the contents of the vial of Longidaza^® 3000 IU in 1.0-2.0 ml of 0.5% procaine (novocaine) solution. In case of procaine (novocaine) intolerance: dissolve Longidaza^® in the same amount of 0.9% sodium chloride solution or water for injection.
2. For the administration using photophoresis to treat onychodystrophy: dilute the contents of the vial of Longidaza^® 3000 IU in 0.5 ml of distilled water, dissolve for 3-4 minutes, apply 1 drop (about 300 IU of Longidaza^®) to the distal phalanges of fingers.
3. For photophoresis or ultraphonophoresis to treat acne vulgaris: dilute 1 vial of Longidaza^® 3000 IU in 2-5 ml of ultrasound gel (Mediagel-T) and apply to the affected area.
4. For the administration using ultrasound to treat contracture: dissolve the contents of the vial of Longidaza 3000 IU in 1.0 ml of physiological solution, mix with 5-7 g of petrolatum, and apply to the scar area.
5. For enhancing bioavailability: dissolve the contents of the vial of Longidaza^® 3000 IU or 1500 IU in 2.0 ml or 1.0 ml of 0.9% sodium chloride solution, respectively.
Inject the solvent into the vial slowly, allow it to stand for 2-3 minutes, and mix gently without shaking so as not to foam the protein.
Do not store the solution prepared for parenteral administration. Do not inject it intravenously!

- hypersensitivity to the active ingredient or to any excipient
- acute infectious diseases
- pulmonary hemorrhage and hemoptysis
- recent vitreous hemorrhage
- acute renal failure
- children and adolescents <18 years of age (no data of clinical studies are available)
- pregnancy

20 ml of the drug is placed into the 3 ml dark glass (hydrolytic class 1) vial hermetically sealed with a rubber stopper and crimped with an aluminum cap. A self-adhesive paper or film label is applied to the vial. 5 vials are placed in a blister container made of polyvinyl chloride film. 1 blister container together with the Patient Information Leaflet in the Kazakh and Russian languages is placed in a cardboard package.

Store at 2°C to 8°C. Do not freeze.
Keep out of reach of children.

2 years.
Do not use the product beyond the expiry date.

NPO Petrovax Pharm LLC, Russia
Legal address:
1 Sosnovaya Street, Pokrov Village, Podolsk, Moscow Region, 142143, Russia.
Tel./Fax: +7 (495) 926-21-07
E-mail: info@petrovax.ru